AxioMx

company

About

AxioMx offers antibody discovery and development services for the research and diagnostics marketplace.

  • 11 - 50

Details

Last Funding Type
Series Unknown
Industries
Biotechnology,Health Diagnostics,Marketplace
Founded date
Jan 1, 2012
Number Of Employee
11 - 50
Operating Status
Active

AxioMx, founded in 2012 and based in Branford, Connecticut is a leader in recombinant antibody technologies. Its founders, Chris McLeod and Dr. Michael Weiner, are life science entrepreneurs who have previously led successful genomics, next-generation sequencing, microfluidics, bioinformatics and proteomic organizations. AxioMx’s unique platform of proprietary phage display libraries, library screening, and affinity maturation methods provides the technical foundation of the company. The company offers a full range of custom antibody discovery and development services for the research and diagnostic market places.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
AxioMx has raised a total of — in funding over 2 rounds. Their latest funding was raised on Apr 30, 2015 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 30, 2015 Series Unknown 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
AxioMx is funded by 1 investors. Advantage Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Advantage Capital Series Unknown